IDEAS home Printed from https://ideas.repec.org/p/ern/wpaper/02-2012.html
   My bibliography  Save this paper

I Farmaci Oncologici in Italia: innovazione e sostenibilità economica

Author

Listed:
  • Fabio Pammolli

    () (Politecnico di Milano and CERM Foundation - Competitività, Regole, Mercati)

  • Massimo Riccaboni

    () (IMT Lucca Institute for Advanced Studies and Department of Managerial Economics, Strategy and Innovation, K.U. Leuven)

  • Nicola Carmine Salerno

    () (Ufficio parlamentare di bilancio)

Abstract

I farmaci innovativi ad alto costo ci fanno toccare con mano quali potranno essere i dilemmi della sanità futura se non si completano le riforme della governance di questo capitolo complesso della spesa pubblica (non solo federalismo, ma sistemi contabili e di reporting, schemi di compartecipazione al costo, screening delle prassi terapeutiche per sollecitare best practice, etc.). Quel trade-off crudo che abbiamo di fronte, tra sostenibilità della spesa e domanda di prestazioni da parte dei cittadini, è, per i farmaci ad alto costo, già una realtà vissuta in tutti gli ospedali. Nella prima parte del rapporto Pammolli, Riccaboni e Salerno descrivono le caratteristiche del comparto, fornendone le grandezze principali attuali e prospettiche, anche in chiave di comparazione internazionale. Nella seconda parte, gli autori approfondiscono il quadro normativo-regolatorio che attualmente presiede alla governance dei farmaci oncologici in Italia. Ne emerge un sistema con ombre e approssimazioni, con impostazioni diverse e spesso incompatibili tra Aifa e Regioni, tra Regione e Regione, addirittura tra Als e Ospedali di una stessa Regione. Un assetto poco trasparente e certo non pronto a governare in maniera positiva e programmatica la forbice tra risorse spendibili e necessità e urgenza delle terapie. Nella parte conclusiva del rapporto si avanzano alcune proposte di policy, distinguendo tra quelle attuabili in tempi brevi e quelle per le quali sono necessari tempi di attuazione più lunghi. Le due tipologie di intervento andrebbero avviate il prima possibile e auspicabilmente condotte in parallelo.

Suggested Citation

  • Fabio Pammolli & Massimo Riccaboni & Nicola Carmine Salerno, 2012. "I Farmaci Oncologici in Italia: innovazione e sostenibilità economica," Working Papers CERM 02-2012, Competitività, Regole, Mercati (CERM).
  • Handle: RePEc:ern:wpaper:02-2012
    as

    Download full text from publisher

    File URL: http://www.cermlab.it/wp-content/uploads/cerm/wp/wpcerm-2012-02.pdf
    File Function: First version, 2012
    Download Restriction: no

    References listed on IDEAS

    as
    1. Sergey V. Buldyrev & Jakub Growiec & Fabio Pammolli & Massimo Riccaboni & H. Eugene Stanley, 2007. "The Growth of Business Firms: Facts and Theory," Journal of the European Economic Association, MIT Press, vol. 5(2-3), pages 574-584, 04-05.
    2. Angus Deaton, 2003. "Health, Inequality, and Economic Development," Journal of Economic Literature, American Economic Association, vol. 41(1), pages 113-158, March.
    3. repec:pri:cheawb:cutler_deaton_lleras-muney_determinants_mortality_nberdec05 is not listed on IDEAS
    4. Fabio Pammolli & Massimo Riccaboni & Laura Magazzini, 2010. "The productivity crisis in pharmaceutical R&D," Working Papers 06/2010, University of Verona, Department of Economics.
    5. repec:pri:rpdevs:cutler_deaton_lleras-muney_determinants_mortality_nberdec05 is not listed on IDEAS
    6. Daron Acemoglu & Joshua Linn, 2004. "Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry," The Quarterly Journal of Economics, Oxford University Press, vol. 119(3), pages 1049-1090.
    7. Carol Corrado & John Haltiwanger & Dan Sichel, 2005. "Measuring Capital in the New Economy," NBER Books, National Bureau of Economic Research, Inc, number corr05-1.
    8. Stefano Capri & Rossella Levaggi, 2010. "Shifting the risk in pricing and reimbursement schemes. A new model of risk-sharing agreements for innovative drugs," LIUC Papers in Economics 234, Cattaneo University (LIUC).
    9. Margaret K. Kyle, 2007. "Pharmaceutical Price Controls and Entry Strategies," The Review of Economics and Statistics, MIT Press, vol. 89(1), pages 88-99, February.
    Full references (including those not matched with items on IDEAS)

    More about this item

    Keywords

    farmaci oncologici; sanità; sostenibilità;

    JEL classification:

    • D40 - Microeconomics - - Market Structure, Pricing, and Design - - - General
    • H50 - Public Economics - - National Government Expenditures and Related Policies - - - General
    • H51 - Public Economics - - National Government Expenditures and Related Policies - - - Government Expenditures and Health
    • H70 - Public Economics - - State and Local Government; Intergovernmental Relations - - - General
    • H75 - Public Economics - - State and Local Government; Intergovernmental Relations - - - State and Local Government: Health, Education, and Welfare
    • H77 - Public Economics - - State and Local Government; Intergovernmental Relations - - - Intergovernmental Relations; Federalism
    • I0 - Health, Education, and Welfare - - General
    • I10 - Health, Education, and Welfare - - Health - - - General
    • I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets
    • I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:ern:wpaper:02-2012. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Guido Bora`). General contact details of provider: http://edirc.repec.org/data/cermmit.html .

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.